Clinical trials: Patients With Cancer
Adenocarcinoma, Ovarian Neoplasms
Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas
2.0 Study Objectives: 2.1 To evaluate the ability of the MiCK assay to predict the outcome of chemotherapy of cancer patients for first-line treatment.
- Conditions
- Adenocarcinoma, Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms
- Trial name
- NCT00443196
- Testing
- MiCK Assay
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Pierian Biosciences
Urinary Bladder Cancer, Bladder Cancer
Study of Vicinium for Treating Patients With Non-Invasive Urothelial Carcinoma In Situ
The purpose of this study is to evaluate the efficacy and tolerability of Vicinium when administered as a monotherapy intravesical instillation in patients with non-invasive urothelial carcinoma in situ (CIS) who failed previous…
- Conditions
- Urinary Bladder Cancer, Bladder Cancer, Bladder Neoplasms, Bladder Tumors
- Trial name
- NCT00462488
- Testing
- Vicinium
- Where
- 21 sites in United States, Canada
- Volunteers
- 46 people
- Sponsor
- Sesen Bio, Inc.
Non Small Cell Lung Cancer
Phase II AZD9291 Open Label Study in NSCLC After Previous EGFR TKI Therapy in EGFR and T790M Mutation Positive Tumours
A Phase II, Open Label, Single-arm Study to Assess the Safety and Efficacy of AZD9291 in Patients with Locally Advanced/Metastatic Non Small Cell Lung Cancer whose Disease has Progressed with Previous Epidermal Growth Factor…
- Trial name
- AURA2 (NCT02094261)
- Testing
- AZD9291
- Where
- 44 sites in United States, Canada and 6 more
- Volunteers
- 210 people
- Sponsor
- AstraZeneca
Glioblastoma Multiforme
TTFields Together With Temozolomide and Radiotherapy in Patients With Newly Diagnosed GBM
The study is a prospective, single arm open label study, designed to test the to evaluate the tolerability and safety outcome of newly diagnosed GBM patients treated with NovoTTF-200A concomitant to Radiotherapy/Temozolomide…
- Trial name
- NCT03780569
- Testing
- NovoTTF-200A, Radiotherapy, Temozolomide
- Where
- Israel
- Volunteers
- 10 people
- Sponsor
- NovoCure Ltd.
Advanced or Metastatic Hepatocellular Cancer, Advanced or Metastatic Ovarian Cancer
A Study With Tasquinimod Treating Patients With Hepatocellular, Ovarian, Renal Cell and Gastric Cancers
This was an exploratory proof of concept study to determine the clinical activity of tasquinimod in patients with advanced or metastatic hepatocellular carcinoma, ovarian carcinoma, renal cell carcinoma and gastric carcinoma who…
- Conditions
- Advanced or Metastatic Hepatocellular Cancer, Advanced or Metastatic Ovarian Cancer, Metastatic Renal Cell Cancer, Advanced or Metastatic Gastric Carcinoma
- Trial name
- NCT01743469
- Testing
- Tasquinimod
- Where
- 24 sites in Belgium, Canada and 3 more
- Volunteers
- 201 people
- Sponsor
- Ipsen
Advanced Solid Cancers
Pharmacokinetic Study of CKD-810 and Taxotere to Treat Patient With Advanced Solid Cancer
The purpose of this study is to evaluate safety and the pharmacokinetic characteristics of docetaxel between two docetaxel products in patients with advanced solid cancer.
- Trial name
- 126ASC08Q (NCT01019941)
- Testing
- CKD-810, Taxotere inj.
- Where
- 7 sites in South Korea
- Volunteers
- 44 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Polycystic Ovary Syndrome, Insulin Resistance
Clomifene Citrate Versus Metformin in First-line Treatment of Infertility in Patients With Polycystic Ovary Syndrome and a Resistance to Insulin
The results of studies conducted until now does not determine what the best way to treat infertility in the first line with patients with Polycystic ovary syndrome (PCOS).
- Trial name
- NCT01638988
- Testing
- Metformin, Clomiphene citrate
- Where
- Canada
- Sponsor
- Clinique Ovo
Non-Squamous Non-Small Cell Lung Cancer
A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating Epidermal Growth Factor Receptor (EGFR) Mutation
This multicenter, randomized, double-blind, placebo-controlled study will evaluate the safety and efficacy of onartuzumab in combination with erlotinib in patients with previously untreated, unresectable stage IIIB or IV…
- Trial name
- NCT01887886
- Testing
- erlotinib, onartuzumab
- Where
- 35 sites in United States, France and 6 more
- Volunteers
- 10 people
- Sponsor
- Hoffmann-La Roche
Carcinoma, Hepatocellular, Gastric/Gastroesophageal Junction Cancer
A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer
The purpose of this study was to evaluate the safety, tolerability, pharmacokinetics and preliminary antitumor activity of sitravatinib as monotherapy and in combination with tislelizumab in participants with unresectable locally…
- Trial name
- NCT03941873
- Testing
- Sitravatinib, Tislelizumab
- Where
- 18 sites in China
- Volunteers
- 111 people
- Sponsor
- BeiGene
Soft Tissue Sarcoma
Efficacy and Safety of L19TNF in Previously Treated Patients with Advanced Stage or Metastatic Soft-tissue Sarcoma
Open label, randomized, controlled phase II study preceded by a safety run-in part in subjects with advanced or metastatic soft-tissue sarcoma.
- Trial name
- FLASH (NCT04733183)
- Testing
- Dacarbazine, onfekafusp alfa
- Where
- 23 sites in France, Germany and 3 more
- Volunteers
- 98 people
- Sponsor
- Philogen S.p.A.
Myasthenia Gravis, Generalized
Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG
Efficacy and safety of amifampridine phosphate in improving the activities of daily living for patients with antibody positive MuSK myasthenia gravis.
- Trial name
- NCT03304054
- Testing
- Amifampridine Phosphate
- Where
- 2 sites in United States
- Volunteers
- 93 people
- Sponsor
- Catalyst Pharmaceuticals, Inc.
Colorectal Cancer Metastatic
Capecitabine Plus Aflibercept as Maintenance Therapy Following Capecitabine Plus Oxaliplatin Plus Aflibercept in Patients With Metastatic Colorectal Cancer
Primary Objective: Efficacy: To assess the progression-free survival rate at 10 months in patients on maintenance therapy with capecitabine plus aflibercept.
- Trial name
- Drop and Go (NCT02085005)
- Testing
- Capecitabine, Aflibercept AVE0005, Oxaliplatin SR96669
- Sponsor
- Sanofi
Neuroendocrine Tumor
Retrospective Analysis of Patients Re-treated With Lutetium-177 DOTATATE (Lutathera®)
This was a retrospective non-interventional study evaluating the medical records of patients with neuroendocrine tumor (NET) re-treated with lutetium-177 DOTATATE at a single United States institution - the Excel Diagnostics \&…
- Trial name
- NCT05816720
- Testing
- Lutetium-177 DOTATATE
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Myeloma
A Non-interventional,Observational Post Authorization Study of Patients With Multiple Myeloma Treated With Lenalidomide TR
CC-5013-PASS-TR/A non-interventional, multi-center, observational post authorization safety study of patients with relapsed/refractory multiple myeloma treated with Lenalidomide in Turkey.
- Trial name
- NCT02387879
- Where
- 38 sites in Turkey (Türkiye)
- Volunteers
- 500 people
- Sponsor
- Celgene
Acute Lymphoblastic Leukemia (ALL)
Safety and Efficacy of Marqibo in Relapsed Acute Lymphoblastic Leukemia
This was a Phase 2, international, multicenter, open-label, single-arm trial evaluating Marqibo (VSLI) in adult subjects with: 1) Ph- ALL or lymphoblastic lymphoma in second or greater relapse; or 2) Ph- ALL or lymphoblastic…
- Trial name
- NCT00495079
- Testing
- Marqibo® (vincristine sulfate liposomes injection)
- Where
- 33 sites in United States, Canada and 3 more
- Volunteers
- 65 people
- Sponsor
- Spectrum Pharmaceuticals, Inc
Malignant Solid Tumors
Genakumab Alone and in Combination With Tislelizumab in Patients With Advanced Malignant Solid Tumors
This is a phase I, multicenter, open-label dose escalation and expansion study to evaluate genakumab alone and in combination with tislelizumab in adult patients with advanced solid malignancies.
- Trial name
- NCT05441046
- Testing
- Genakumab
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Colorectal Cancer, Non-small Cell Lung Cancer
Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib
This is a Phase 1 open-label, dose-escalation trial using "3+3" design, evaluating MM-151 co-administration with MM-121, MM-141, and trametinib at varying dose levels.
- Conditions
- Colorectal Cancer, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
- Trial name
- NCT02538627
- Testing
- MM-151, MM-121, MM-141
- Where
- 5 sites in United States
- Volunteers
- 5 people
- Sponsor
- Merrimack Pharmaceuticals
Breast Cancer
A Study of The Safety Profile of First-line Avastin (Bevacizumab) in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Her2-negative Breast Cancer (AVATAX)
This single arm, open label study will assess the safety profile of Avastin (bevacizumab) in combination with paclitaxel as first-line treatment in patients with locally recurrent or metastatic Her2-negative breast cancer.
- Trial name
- NCT01156961
- Testing
- bevacizumab [Avastin], paclitaxel
- Sponsor
- Hoffmann-La Roche
Leukemia, Myeloid, Chronic
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia in Accelerated or Blast Phase
This study will evaluate the efficacy and safety of LBH589B in adult patients with chronic myeloid leukemia who are in accelerated phase or blast phase (blast crisis) with resistant disease following treatment with at least two…
- Trial name
- NCT00449761
- Testing
- LBH589
- Where
- 26 sites in United States, Germany
- Volunteers
- 27 people
- Sponsor
- Novartis Pharmaceuticals
Biliary Tract Cancer
A Clinical Study of PD-L1 Antibody ZKAB001 Combined With Capecitabine in Resected Biliary Tract Cancer
This is a Phase Ib, open-label,single-arm, clinical study, aiming to investigate the safety, tolerability and pharmacokinetics of ZKAB001 (a fully human monoclonal antibody targeting the Programmed Death - Ligand 1 (PD-L1)…
- Trial name
- NCT04608786
- Testing
- ZKAB001 5mg/kg, Capecitabine
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Lee's Pharmaceutical Limited
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.